Device Trial Radar · NCT07228117
GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes
Last checked: Nov 19, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
389
Actual
Start
Feb 2, 2026
Primary completion
Jan 2027
Study completion Jan 2027
Sponsor
- Lead sponsor
- Medtronic MiniMed, Inc.Public (MDT)
- Sponsor type
- Industry
- First posted
- Nov 14, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Other
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 7 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to check that a new insulin pump, called NMX8, is safe when used with a continuous glucose monitoring sensor called Disposable Sensor 5/Simplera Sync in people with diabetes. The study will include people with Type 1 diabetes who are 7-85 years old and people with Type 2 diabetes who are 18-85 years old. Participants will use their current therapy while also wearing the DS5/Simplera sensor for up to 40 days. During this time, they will complete a meal and exercise log. Participants will then be placed into one of three groups by chance and given the NMX8 pump to use for about 90 days. During this time, participants will bolus, not bolus, or bolus at will for meals and continue to complete a meal and exercise log depending on the group they are in. Once their part in the study is over, if participants like the pump and want to keep using it, they may be able to join a Continued Access Period to keep using the NMX8 pump.
Conditions
- Type 1 Diabetes Mellitus
- Type 2 Diabetes Mellitus
Interventions
MiniMed™ NMX8-AID System with DS5™/Simplera Sync™Device
Patients will be provided with the NMX8 system with DS5/Simplera Sync CGM.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Study Arm 1: Percent of Time in Range (TIR 70-180 mg/dL)Time frame: Throughout the study period, approximately 90 days.
- Study Arm 1: Percent of Time in Hypoglycemia (< 70 mg/dL)Time frame: Throughout the study period, approximately 90 days.
- Study Arm 2: Percent of Time in Range (TIR 70-180 mg/dL)Time frame: Throughout the study period, approximately 90 days.
3 more outcomes with a free account
Locations
33 sites in 3 countries. Site status is shown where the registry gives one.
Medical Investigations
Little Rock, Arkansas
Headlands Research California, LLC
Escondido, California
Sansum Diabetes Research Institute
Goleta, California
30 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.